EricBluemnMD

Physician

Dr. Bluemn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
333 N 1st St
Ste 280
Boise, ID 83702
Phone+1 208-345-6545

Fax+1 208-345-1213

PubMed

453 citations
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Eric G. Bluemn, Ilsa Coleman, Jared M. Lucas, Roger Coleman, Susana Hernandez-Lopez
Cancer Cell. 2017-10-09
101 citations
The androgen/androgen receptor axis in prostate cancer.
Eric G. Bluemn, Peter S. Nelson
Current Opinion in Oncology. 2012-05-01
5 citations
Analysis of Thirty-Day Readmission after Infrainguinal Bypass.
Eric G. Bluemn, Julie M. Flahive, Alik Farber, Daniel J. Bertges, Philip P. Goodney
Annals of Vascular Surgery. 2019-07-23

Journal Articles

NESVS12. Analysis of 30-Day Readmission After Infrainguinal Bypass: Lessons Learned from a Trial of 30-Day Data Collection in the Vascular Study Group of New England
Eric G Bluemn, Francesco A Aiello, Daniel J Bertges, Alik Farber, Philip P Goodney, Andres Schanzer, Jessica P Simons, Journal of Vascular Surgery

NESVS12. Analysis of 30-Day Readmission After Infrainguinal Bypass: Lessons Learned from a Trial of 30-Day Data Collection in the Vascular Study Group of New EnglandSeptember 2018

Targeted Therapies Push Metastatic Prostate Cancer in New DirectionsNovember 14th, 2017